Multi-organ benefits of incretin agonists

IF 50 1区医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY Nature Medicine Pub Date : 2024-12-13 DOI:10.1038/s41591-024-03391-y

Karen O’Leary

引用次数: 0

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

肠促胰岛素激动剂的多器官益处

在成功的临床试验和减肥批准之后，今年越来越多的证据报道支持肠促胰岛素激动剂——包括semagludide （GLP-1受体激动剂）和tizepatide （GLP-1和GIP受体激动剂）——对心血管和肾脏功能的积极作用。FLOW试验显示，在2型糖尿病和慢性肾脏疾病患者中，接受西马鲁肽治疗的患者发生主要肾脏疾病事件（包括肾衰竭、心血管事件和死亡）的风险比接受安慰剂治疗的患者低24%。一项预先指定的分析表明，无论是否同时使用SGLT2抑制剂（用于肾脏保护），这些益处都是一致的。更积极的消息来自于替西帕肽的SUMMIT试验，该试验降低了心力衰竭事件的风险，并改善了保留射血分数和肥胖的心力衰竭患者的症状和身体限制。原始参考文献：N. Engl。中华医学杂志，1999,19 (2)；心血管病。J. Med. https://doi.org/10.1056/NEJMoa2410027 （2024）

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Nature Medicine 医学-生化与分子生物学

CiteScore

100.90

自引率

0.70%

发文量

525

审稿时长

1 months

期刊介绍： Nature Medicine is a monthly journal publishing original peer-reviewed research in all areas of medicine. The publication focuses on originality, timeliness, interdisciplinary interest, and the impact on improving human health. In addition to research articles, Nature Medicine also publishes commissioned content such as News, Reviews, and Perspectives. This content aims to provide context for the latest advances in translational and clinical research, reaching a wide audience of M.D. and Ph.D. readers. All editorial decisions for the journal are made by a team of full-time professional editors. Nature Medicine consider all types of clinical research, including: -Case-reports and small case series -Clinical trials, whether phase 1, 2, 3 or 4 -Observational studies -Meta-analyses -Biomarker studies -Public and global health studies Nature Medicine is also committed to facilitating communication between translational and clinical researchers. As such, we consider “hybrid” studies with preclinical and translational findings reported alongside data from clinical studies.